Breakthrough gene therapy could preserve vision
August 17th, 2010 - 5:34 pm ICT by ANIWashington, Aug 17 (ANI): Non-viral gene therapy can delay the onset of some forms of eye disease and preserve vision, found one of only two studies of its kind.
Researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts developed nanoparticles to deliver therapeutic genes to the retina and found that treated mice temporarily retained more eyesight than controls.
The study brings researchers closer to a non-viral gene therapy treatment for degenerative eye disorders.
“Our work shows that it is possible to attain therapeutic results using non-viral gene delivery methods, specifically, nanoparticles. Nanoparticles, which are small enough to penetrate cells and stable enough to protect DNA, are capable of preventing retinal cell death and preserving vision,” said senior author Dr. Rajendra Kumar-Singh.
“The most common approach to gene therapy involves using a virus to deliver DNA to cells. While viruses are very efficient carriers, they can prompt immune responses that may lead to inflammation, cancer, or even death. Non-viral methods offer a safer alternative, but until now, efficiency has been a significant barrier,” added Kumar-Singh.
In a model simulating the progression of human retinal degeneration, the researchers treated mice with nanoparticles carrying a gene for GDNF (Glial Cell Line-Derived Neurotrophic Factor), a protein known to protect the photoreceptor cells in the eye.
Retinas treated with the GDNF-carrying nanoparticles showed significantly less photoreceptor cell death than controls.
Preservation of these cells resulted in significantly better eyesight in the treatment group seven days after treatment, compared to controls.
The protection conferred by the GDNF-carrying nanoparticles was temporary, as tests fourteen days after treatment showed no difference in eyesight between treated mice and controls.
“The next step in this research is to prolong this protection by adding elements to the DNA that permit its retention in the cell. Bringing forth a more potent and enduring result will move us closer to clinical application of non-viral gene therapy,” said Kumar-Singh.
The study is published online in advance of print in Molecular Therapy. (ANI)
- Promising results of gene therapy to treat eye diseases - Aug 14, 2010
- Indian origin scientist's gene therapy shows promise in slowing AMD - Apr 30, 2011
- New prosthetic device offers to hope to the visually impaired - Nov 19, 2010
- Night blindness cured in mice with special cells - Apr 19, 2012
- New hope for restoring vision in the blind - Sep 22, 2010
- Stem cell therapy for age-related macular degeneration may soon be a reality - Mar 25, 2011
- New study on lead exposure paves way for blindness treatment - Oct 26, 2010
- Researchers isolate protective mechanism to save sight - Nov 17, 2009
- Gene discovery could pave way for nearsightedness treatments - Sep 13, 2010
- Novel way to prevent blindness caused by retinitis pigmentosa - Jun 12, 2010
- 'Deathstalker' scorpion venom could improve anti-brain cancer gene therapy - Aug 12, 2010
- Gene therapy to treat blindness on the anvil - Aug 01, 2009
- Single shot of gene therapy could make kids with congenital blindness see - Oct 25, 2009
- Drug therapy shows promise in treating leading cause of childhood blindness - Feb 17, 2011
- Blind man's sight restored after 55 years - Jun 18, 2011
Tags: cell death, delivery methods, eye disease, eye disorders, fourteen days, gene delivery, gene therapy treatment, glial cell, graduate biomedical sciences, immune responses, photoreceptor cells, rajendra kumar, retinal cell, retinal degeneration, sackler school, therapeutic genes, therapeutic results, tufts university school, tufts university school of medicine, viral gene